Patent intelligence · US
US 8101712
Purification processes for echinocandin-type compounds
Purification processes for echinocandin-type compounds
Patent details — US 8101712
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 24, 2012
- Expiration
- Jan 19, 2032
- Claims
- 21
- CPC classes
- A61P, A61P31/04
Quick answer
US 8101712 (Purification processes for echinocandin-type compounds) is held by TEVA Gyógyszergyár Zártkör{acute over ())}{acute over (})}úen M{acute over ())}{acute over (})}úköd{acute over ())}{acute over (})}ó Részvénytársaság. Status: granted. Granted Jan 24, 2012. Expires Jan 19, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61P, A61P31/04
More from TEVA Gyógyszergyár Zártkör{acute over ())}{acute over (})}úen M{acute over ())}{acute over (})}úköd{acute over ())}{acute over (})}ó Részvénytársaság
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 8101712?
US 8101712 (Purification processes for echinocandin-type compounds) is held by TEVA Gyógyszergyár Zártkör{acute over ())}{acute over (})}úen M{acute over ())}{acute over (})}úköd{acute over ())}{acute over (})}ó Részvénytársaság. Status: granted. Granted Jan 24, 2012. Expires Jan 19, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8101712?
TEVA Gyógyszergyár Zártkör{acute over ())}{acute over (})}úen M{acute over ())}{acute over (})}úköd{acute over ())}{acute over (})}ó Részvénytársaság is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 8101712 expire?
Our index shows an expiration date of Jan 19, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.